{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:52Z","timestamp":1772120032111,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hyperglycemia is associated with abnormalities of lipoproteins. The aim of this study was to analyze, in patients with Type 1 Diabetes (T1D), the association of glycemic control with lipid profile, focusing on glycemic variability and time in range obtained from Continuous Glucose Monitoring (CGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a retrospective cohort in patients with T1D. We analyzed clinical parameters, HbA1c, CGM and lipid profile in two moments 6 to 18 months apart. We evaluated the association of HbA1c and CGM metrics with lipid profile in cross-sectional (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009242) and longitudinal (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200990) analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the study population was 36.6\u2009\u00b1\u200912.6 years, 51.7% were male, and the mean diabetes duration was 16.8\u2009\u00b1\u200910.3 years. In the cross-sectional analysis, higher HbA1c, higher glucose management indicator (GMI), higher time above range and lower time in range were associated with higher triglyceride levels. In the longitudinal analysis, an increase in time below range was associated with a decrease of HDL cholesterol. In both analyses, an increase in the coefficient of variability (CV) was associated with a significant decrease of HDL cholesterol. HbA1c and CGM were not associated with total cholesterol or LDL cholesterol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed a negative association between CV and HDL cholesterol levels and a positive association between hyperglycemia metrics and triglyceride levels. These findings suggest that CGM parameters may be a helpful tool to guide the improvement of both glycemic control and lipid profile in T1D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-023-03464-x","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T01:01:31Z","timestamp":1701738091000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of glycemic variability and time in range with lipid profile in type 1 diabetes"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-0047","authenticated-orcid":false,"given":"Mariana","family":"Salsa-Castelo","sequence":"first","affiliation":[]},{"given":"Celestino","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"issue":"21","key":"3464_CR1","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"M. Lind et al. Glycemic control and excess mortality in type 1 diabetes. N. Engl. J. Med. 371(21), 1972\u20131982 (2014)","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"3464_CR2","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.2337\/db15-1517","volume":"65","author":"Group, D.C.a.C.T.E.o.D.I.a.C.D.E.R.,","year":"2016","unstructured":"Group, D.C.a.C.T.E.o.D.I.a.C.D.E.R., Risk Factors for Cardiovascular Disease in Type 1. Diabetes. Diabetes 65(5), 1370\u20131379 (2016)","journal-title":"Diabetes. Diabetes"},{"issue":"6","key":"3464_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tem.2020.01.015","volume":"31","author":"B Verg\u00e8s","year":"2020","unstructured":"B. Verg\u00e8s, Dyslipidemia in Type 1 Diabetes: AMaskedDanger. Trends Endocrinol. Metab. 31(6), 422\u2013434 (2020)","journal-title":"Trends Endocrinol. Metab."},{"issue":"3","key":"3464_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc08-1775","volume":"32","author":"J Guy","year":"2009","unstructured":"J. Guy et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care 32(3), 416\u2013420 (2009)","journal-title":"Diabetes Care"},{"issue":"12","key":"3464_CR5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s00125-010-1886-6","volume":"53","author":"DM Maahs","year":"2010","unstructured":"D.M. Maahs et al. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia 53(12), 2518\u20132525 (2010)","journal-title":"Diabetologia"},{"issue":"12","key":"3464_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2337\/dc17-1600","volume":"40","author":"T Danne","year":"2017","unstructured":"T. Danne et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 40(12), 1631\u20131640 (2017)","journal-title":"Diabetes Care"},{"issue":"5","key":"3464_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"IHS Group","year":"2019","unstructured":"I.H.S. Group, Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 7(5), 385\u2013396 (2019)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"3464_CR8","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.2337\/diacare.23.12.1830","volume":"23","author":"TS Temelkova-Kurktschiev","year":"2000","unstructured":"T.S. Temelkova-Kurktschiev et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23(12), 1830\u20131834 (2000)","journal-title":"Diabetes Care"},{"key":"3464_CR9","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/jcm10071477","volume":"10","author":"MC Nwadiugwu","year":"2022","unstructured":"M.C. Nwadiugwu, et al. Identifying Glycemic Variability in Diabetes Patient Cohorts and Evaluating Disease Outcomes. J. Clin. Med. 10, 1477 (2022)","journal-title":"J. Clin. Med."},{"issue":"Supplement_1","key":"3464_CR10","first-page":"S83","volume":"45","author":"Committee, A.D.A.P.P","year":"2021","unstructured":"Committee, A.D.A.P.P Glycemic Targets: Standards of Medical Care in Diabetes\u20142022. Diabetes Care 45(Supplement_1), S83\u2013S96 (2021)","journal-title":"Diabetes Care"},{"issue":"3","key":"3464_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1161\/01.CIR.103.3.346","volume":"103","author":"SM Haffner","year":"2001","unstructured":"S.M. Haffner, Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation 103(3), 346\u2013347 (2001)","journal-title":"Circulation"},{"issue":"2","key":"3464_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1161\/01.CIR.0000134501.57864.66","volume":"110","author":"K Esposito","year":"2004","unstructured":"K. Esposito et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110(2), 214\u2013219 (2004)","journal-title":"Circulation"},{"issue":"14","key":"3464_CR13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jama.295.14.1681","volume":"295","author":"L Monnier","year":"2006","unstructured":"L. Monnier et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama 295(14), 1681\u20131687 (2006)","journal-title":"Jama"},{"issue":"6","key":"3464_CR14","first-page":"1659","volume":"79","author":"DJ Cox","year":"1994","unstructured":"D.J. Cox et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J. Clin. Endocrinol. Metab. 79(6), 1659\u20131662 (1994)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"18","key":"3464_CR15","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1001\/archinte.160.18.2756","volume":"160","author":"A P\u00e9rez","year":"2000","unstructured":"A. P\u00e9rez et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch. Intern. Med. 160(18), 2756\u20132762 (2000)","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"3464_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-021-00863-x","volume":"21","author":"R Huang","year":"2021","unstructured":"R. Huang, L. Yan, Y. Lei, The relationship between high-density lipoprotein cholesterol (HDL-C) and glycosylated hemoglobin in diabetic patients aged 20 or above: a cross-sectional study. BMC Endocr. Disord. 21(1), 198 (2021)","journal-title":"BMC Endocr. Disord."},{"issue":"5","key":"3464_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.diabet.2009.04.004","volume":"35","author":"B Verg\u00e8s","year":"2009","unstructured":"B. Verg\u00e8s, Lipid disorders in type 1 diabetes. Diabetes Metab. 35(5), 353\u2013360 (2009)","journal-title":"Diabetes Metab."},{"key":"3464_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/biomedicines9070826","volume":"9","author":"ST O\u2019Brien","year":"2021","unstructured":"S.T. O\u2019Brien, O.M. Neylon, T. O\u2019Brien, Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities. Biomedicines 9, 826 (2021)","journal-title":"Biomedicines"},{"issue":"3","key":"3464_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","volume":"86","author":"IJ Goldberg","year":"2001","unstructured":"I.J. Goldberg, Diabetic Dyslipidemia: Causes and Consequences. J. Clin. Endocrinol. Metab. 86(3), 965\u2013971 (2001)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"3464_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2337\/diacare.19.7.689","volume":"19","author":"VA Koivisto","year":"1996","unstructured":"V.A. Koivisto et al. Cardiovascular Disease and Its Risk Factors in IDDM in Europe. Diabetes Care 19(7), 689\u2013697 (1996)","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"3464_CR21","first-page":"S144","volume":"45","author":"Committee, A.D.A.P.P","year":"2021","unstructured":"Committee, A.D.A.P.P, Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes\u20142022. Diabetes Care 45(Supplement_1), S144\u2013S174 (2021)","journal-title":"Diabetes Care"},{"issue":"1","key":"3464_CR22","first-page":"74","volume":"14","author":"H Cardoso","year":"2019","unstructured":"H. Cardoso, et al. National Consensus in the use of the Flash Glucose Monitoring System in Portugal. Rev. Port. Endocrinol. Diabetes Metab. 14(1), 74\u201381 (2019)","journal-title":"Rev. Port. Endocrinol. Diabetes Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03464-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T03:35:17Z","timestamp":1705980917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03464-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["3464"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03464-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2943647\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}